About Xias Bio
Xias Bio is a Healthcare company based in United States founded in 2020. It operates as a developer of recombinant proteins. Xias Bio has raised $5.23 million across 2 funding rounds from investors including IndieBio, Happiness Capital and SOSV. Xias Bio offers products and services including LiteProteins, Resilite, ElastiLite, LamiLite, and Keralite. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics. Its legal entity is XIAS BIO LIMITED. Its competitors include Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Xias Bio was founded in 2020 in the United States as a developer of recombinant proteins within the biotechnology sector. Non-immunogenic natural motifs are altered by the company to create enhanced delivery platforms. These materials are applied in areas including cell culture, drug delivery, and cosmeceuticals. Operations focus on producing functional proteins for research and industrial uses.
- Headquarters United States
- SectorsHealthcare
- Email••••••••
- Website xiasbio.com
- Social LinkedIn X
- Legal Name Xias Bio Limited
- Total Equity Funding$5.23M (USD)
in 2 rounds
- Latest Funding Round$4.98M (USD), Seed
Sep 2024
- InvestorsIndieBio
& 5 more
Products & Services of Xias Bio
Xias Bio offers a comprehensive portfolio of products and services, including LiteProteins, Resilite, ElastiLite, LamiLite, and Keralite.
Platform for creating sustainable multi-function protein alternatives.
Multi-function protein for cosmetics and biotech applications.
High-performance protein for enhanced product innovations.
Sustainable protein for personal care and biotech uses.
Engineered protein for manufacturing and applications.
Multi-function protein for various industry needs.
Sustainable alternative for biotech and cosmetics.
Optimized protein for performance in multiple sectors.
Protein for innovative product development.
Tailored proteins for specific biotech requirements.
Funding Insights of Xias Bio
Xias Bio has successfully raised a total of $5.23M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.98 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.23M
- Total Rounds 2
- Last Round Seed — $4.98M
- First Round $250,000
(Dec 2023)
- Investors Count 6
All 2 funding rounds of Xias Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $4.98M | Seed | – | – | |
| Dec 2023 | $250,000 | Seed | – | IndieBio | – |
6 investors in total: 6 institutional.
Investors in Xias Bio
Xias Bio has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include IndieBio, Happiness Capital and SOSV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are accelerated through IndieBio's focused programs. | – | indiebio.co | San Francisco, United States | |
- | – | happinesscapital.com | - | |
- | – | sosv.com | - | |
- | – | goodstartup.com | - | |
- | – | cptcap.com | - | |
- | – | boxone.xyz | - |
Investor details for Xias Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xias Bio
1 people are tracked at Xias Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
David J Harvey | Managing Director | Leadership |
Complete people profiles for Xias Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xias Bio
3 dated milestones of Xias Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Xias Bio is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Seed, of $5.0M.
Competitors of Xias Bio
Xias Bio has 9 listed competitors in our database, 9 of them funded. They include Candel Therapeutics, StrideBio, Genedit, Phase Genomics and Genenta Science, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| genenta.com | 2014 | Milan, Italy | $33.58M | – | Lentivirus-based gene and cell therapies for cancer are developed. | |
| sixfold.bio | 2017 | London, United Kingdom | $4.59M | 16 | Oligonucleotide delivery systems are developed for targeted gene therapy. | |
| feldan.com | 2007 | Quebec, Canada | $52.9M | – | Proteins are delivered directly into cells via proprietary shuttle technology. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| qkine.com | 2016 | Cambridge, United Kingdom | $8.15M | 15 | Animal-free growth factors are developed for life science applications. |
Detailed competitors of Xias Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xias Bio
The website of Xias Bio (xiasbio.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 2037.3% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Xias Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xias Bio
Xias Bio was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Xias Bio is headquartered in United States.
Xias Bio is a funded company, having raised a total of $5.23M across 2 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Dec 2023.
Xias Bio was founded in 2020 in the United States as a developer of recombinant proteins within the biotechnology sector. Non-immunogenic natural motifs are altered by the company to create enhanced delivery platforms. These materials are applied in areas including cell culture, drug delivery, and cosmeceuticals. Operations focus on producing functional proteins for research and industrial uses.
Xias Bio's top competitors include Phase Genomics, Genenta Science and Genedit.
Xias Bio offers LiteProteins, Resilite, ElastiLite, LamiLite, and 6 more products and services.
Xias Bio has 6 investors. Key investors include IndieBio, Happiness Capital, SOSV, Good Startup, and CPT Capital.
Xias Bio operates through Xias Bio Limited.